title: Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal women.
abstract: Endocrine therapy remains important in premenopausal women with hormone receptor positive breast cancer. Ovarian ablation, used alone, is effective in delaying recurrence and increasing survival in such women. When added to chemotherapy, it is less clear that it is effective perhaps because of the endocrine ablative effect of chemotherapy. Trials comparing ovarian ablation with or without tamoxifen to CMF-type chemotherapy suggest that the endocrine therapy is equivalent to or better than this chemotherapy in women whose tumors have estrogen and/or progesterone receptor. Tamoxifen is also effective in preventing recurrence and prolonging survival in the adjuvant setting in premenopausal women. While most of the available data deals with tamoxifen given alone, it appears to have a similar beneficial effect when added to chemotherapy in the premenopausal adjuvant setting. Adjuvant aromatase inhibitors should not be used in premenopausal women.
authors.affiliation: Breast Cancer Site Group, Toronto Sunnybrook Regional Cancer Centre, Canada. kathy.pritchard@sw.ca <kathy.pritchard@sw.ca>
authors.forename: Kathleen
authors.initials: K
authors.lastname: Pritchard
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives; D006801:Humans; D009364:Neoplasm Recurrence, Local; D017697:Premenopause; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D013534:Survival; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen; D007987:Gonadotropin-Releasing Hormone
references.citation: J Clin Oncol. 2001 Jan 15;19(2):343-53
references.pmid: 11208825
references.citation: J Clin Oncol. 2003 Feb 1;21(3):453-7
references.pmid: 12560434
references.citation: J Clin Oncol. 1998 Aug;16(8):2651-8
references.pmid: 9704715
references.citation: Trans Med Chir Soc Edinb. 1896;15:153-179
references.pmid: 29584099
references.citation: N Engl J Med. 1988 Dec 29;319(26):1681-92
references.pmid: 3205265
references.citation: J Natl Cancer Inst. 1998 Sep 16;90(18):1346-60
references.pmid: 9747866
references.citation: Br J Cancer. 1988 Jun;57(6):608-11
references.pmid: 2900647
references.citation: Br Med J. 1973 Jan 6;1(5844):13-4
references.pmid: 4567104
references.citation: J Clin Oncol. 1998 Feb;16(2):470-9
references.pmid: 9469330
references.citation: J Clin Oncol. 2001 Sep 15;19(18):3808-16
references.pmid: 11559718
references.citation: J Clin Oncol. 2002 Mar 15;20(6):1467-72
references.pmid: 11896093
references.citation: Lancet. 1985 Jan 5;1(8419):16-9
references.pmid: 2856949
references.citation: Cancer Treat Rep. 1980 Jun-Jul;64(6-7):787-96
references.pmid: 7427962
references.citation: Lancet. 1998 May 16;351(9114):1451-67
references.pmid: 9605801
references.citation: N Engl J Med. 1989 Feb 23;320(8):479-84
references.pmid: 2644532
references.citation: J Clin Oncol. 2002 Dec 15;20(24):4628-35
references.pmid: 12488406
references.citation: Eur J Cancer. 1999 Nov;35(12):1625-7
references.pmid: 10674005
references.citation: Br J Cancer. 1988 Jun;57(6):601-3
references.pmid: 3044432
references.citation: Lancet. 1987 Jul 25;2(8552):171-5
references.pmid: 2885637
references.citation: J Clin Oncol. 1992 Apr;10(4):599-605
references.pmid: 1548522
references.citation: Eur J Cancer. 1999 Nov;35(12):1659-66
references.pmid: 10674010
references.citation: J Natl Cancer Inst. 2000 Dec 20;92(24):1991-8
references.pmid: 11121461
references.citation: J Clin Oncol. 1992 Jul;10(7):1049-56
references.pmid: 1351538
references.citation: Eur J Cancer. 1991;27(8):966-70
references.pmid: 1832904
references.citation: J Clin Oncol. 1998 Mar;16(3):994-9
references.pmid: 9508182
references.citation: J Clin Oncol. 2000 Jul;18(14):2718-27
references.pmid: 10894871
references.citation: Lancet. 1992 Jan 11;339(8785):95-6
references.pmid: 1345872
references.citation: J Natl Cancer Inst. 1998 Sep 16;90(18):1361-70
references.pmid: 9747867
references.citation: Lancet. 1993 May 22;341(8856):1293-8
references.pmid: 8098446
references.citation: Lancet. 1992 Jan 11;339(8785):71-85
references.pmid: 1345869
references.citation: J Clin Oncol. 2002 Dec 15;20(24):4611-4
references.pmid: 12488402
references.citation: Ann Oncol. 2001 Aug;12(8):1081-9
references.pmid: 11583189
references.citation: Eur J Cancer. 2007 Jan;43(2):331-40
references.pmid: 17134892
references.citation: J Clin Oncol. 2002 Dec 15;20(24):4621-7
references.pmid: 12488405